


# Unleashing the Potential of Vision-Language Pre-Training for 3D Zero-Shot Lesion Segmentation via Mask-Attribute Alignment

Yankai Jiang<sup>1</sup>, Wenhui Lei<sup>1,2</sup>, Xiaofan Zhang<sup>1,2</sup>, Shaoting Zhang<sup>1</sup>


<sup>1</sup>Shanghai Al Laboratory <sup>2</sup>Shanghai Jiao Tong University

### **Background**

#### Vision-language pre-training methods, e.g., CLIP, has illuminated a new paradigm for zero-shot object recognition.



This breakthrough also paves the way for significant advancements in zero-shot disease detection and diagnosis.



#### **Motivation**

Can we leverage the zero-shot capability of vision-language pre-training for 3D lesion segmentation?

Given the diversity and prevalence of new anomalies in clinical scenarios, along with the challenges of medical data collection, there is an increasing demand for zero-shot models capable of handling unseen diseases in an open-set setting.

#### **Challenges:**

- The substantial gap between the upstream contrastive pre-training task and the downstream per-pixel dense prediction task. The former focuses on aligning image-level global representations with text embeddings, while the latter requires fine-grained lesion-level visual understanding.
- Lesions can exhibit significant variations in shape and size, and present with blurred boundaries. Models struggle when encountering unseen lesion types due to their out-of-distribution visual characteristics. Simply using text inputs, such as raw reports, or common knowledge of disease definitions, is insufficient.

www.shlab.org.cn

## **Key Ideas**

02


03

O1 Leveraging multiscale mask representations with inherent boundary information to capture diverse lesion regions.

To learn extensible text representations that are robust to the outof-distribution visual characteristics of unseen lesions, we incorporate domain knowledge from human experts to structure textual reports into descriptions of various elemental disease visual attributes (e.g., shape, intensity, location).

Multi-scale mask-attribute alignment aligns disease region features with different attributes, forming multiple positive pairs for each lesion mask to establish fine-grained relationships between visual features and various disease attributes.

Cross-Modal Knowledge Injection (CMKI) module leverages both enhanced mask and attribute embeddings to generate predictions



D2

E Structured Reports

Lesion 1: Liver Tumor

© Location: Liver

○ Shape: Round-like

△ Density: Hypodense

◇ Density Variation: ...


○ Enhancement Status: ...

☆ Surface Characteristics: ...


☆ Relationship with Organs:

△ Specific Features: ...

Lesion 2: Liver Tumor




## **Training**



- Utilization of Multi-Scale Features.
- Dissecting Reports into Descriptions of Fundamental Disease Attributes.
- Multi-Positive Contrastive Loss
- Cross-Modal Knowledge Injection

## **Testing**



- Step-I: Image Partitioning via Mask Tokens. Test CT images are divided into regions, each represented by mask tokens.
- Step-II: Mask-attribute matching. Each mask token is associated with stored attribute embeddings.
- Step-III: Cross-modal fusion and mask prediction. Information from mask tokens and text embeddings is fused to generate segmentation masks.
- Step-IV: Disease identification via attribute-querying. The Clinical Knowledge Table links the predicted attributes to specific disease categories for precise diagnosis.

## **Results**


#### Segmentation Performance on Seen Classes

		KiTS23								
Method Colon Tumor		Pancreas Tumor		Liver	Tumor	Lung	<u>Fumor</u>	Kidney Cyst		
DSC↑	NSD↑	DSC↑	NSD↑	DSC↑	NSD↑	DSC↑	NSD↑	DSC↑	NSD↑	
44.78±16.21	54.14±15.67	38.85±10.25	54.72±11.59	60.05±5.29	72.88±5.98	67.13±6.08	68.89±7.22	48.43±14.04	52.32±15.62	
47.02±15.85	57.36±14.33	37.97±10.54	53.98±11.86	61.33±5.01	73.27±5.44	69.50±5.61	71.39±6.55	48.76±13.82	52.96±15.19	
46.87±16.02	55.28±15.52	38.72±10.33	54.01±11.67	62.37±4.88	74.75±5.09	68.95±5.67	71.03±6.82	48.06±14.26	52.11±16.05	
51.02±14.62	60.93±13.36	42.40±9.54	58.54±10.79	64.25±3.94	77.06±4.21	67.27±5.71	69.33±6.95	50.25±12.24	54.17±13.53	
53.55±13.49	62.41±12.81	43.30±9.29	59.63±10.55	65.18±3.74	78.95±4.03	70.96±5.56	72.34±6.29	51.60±11.84	55.41±12.99	
	DSC↑  44.78±16.21  47.02±15.85  46.87±16.02  51.02±14.62	DSC↑         NSD↑           44.78±16.21         54.14±15.67           47.02±15.85         57.36±14.33           46.87±16.02         55.28±15.52           51.02±14.62         60.93±13.36	DSC↑         NSD↑         DSC↑           44.78±16.21         54.14±15.67         38.85±10.25           47.02±15.85         57.36±14.33         37.97±10.54           46.87±16.02         55.28±15.52         38.72±10.33           51.02±14.62         60.93±13.36         42.40±9.54	$\begin{array}{ c c c c c c }\hline Colon Tumor & Pancreas Tumor \\\hline DSC\uparrow & NSD\uparrow & DSC\uparrow & NSD\uparrow \\\hline \hline 44.78\pm16.21 & 54.14\pm15.67 & 38.85\pm10.25 & 54.72\pm11.59 \\\hline 47.02\pm15.85 & 57.36\pm14.33 & 37.97\pm10.54 & 53.98\pm11.86 \\\hline 46.87\pm16.02 & 55.28\pm15.52 & 38.72\pm10.33 & 54.01\pm11.67 \\\hline 51.02\pm14.62 & 60.93\pm13.36 & 42.40\pm9.54 & 58.54\pm10.79 \\\hline \end{array}$	$\begin{array}{ c c c c c c c c }\hline DSC\uparrow & NSD\uparrow & DSC\uparrow & NSD\uparrow & DSC\uparrow \\\hline 44.78\pm16.21 & 54.14\pm15.67 & 38.85\pm10.25 & 54.72\pm11.59 & 60.05\pm5.29 \\ 47.02\pm15.85 & 57.36\pm14.33 & 37.97\pm10.54 & 53.98\pm11.86 & 61.33\pm5.01 \\ 46.87\pm16.02 & 55.28\pm15.52 & 38.72\pm10.33 & 54.01\pm11.67 & 62.37\pm4.88 \\ 51.02\pm14.62 & 60.93\pm13.36 & 42.40\pm9.54 & 58.54\pm10.79 & 64.25\pm3.94 \\\hline \end{array}$	$\begin{array}{ c c c c c c c c c }\hline Colon Tumor & Pancreas Tumor & Liver Tumor \\\hline DSC\uparrow & NSD\uparrow & DSC\uparrow & NSD\uparrow & DSC\uparrow & NSD\uparrow \\\hline 44.78\pm16.21 & 54.14\pm15.67 & 38.85\pm10.25 & 54.72\pm11.59 & 60.05\pm5.29 & 72.88\pm5.98 \\ 47.02\pm15.85 & 57.36\pm14.33 & 37.97\pm10.54 & 53.98\pm11.86 & 61.33\pm5.01 & 73.27\pm5.44 \\ 46.87\pm16.02 & 55.28\pm15.52 & 38.72\pm10.33 & 54.01\pm11.67 & 62.37\pm4.88 & 74.75\pm5.09 \\ 51.02\pm14.62 & 60.93\pm13.36 & 42.40\pm9.54 & 58.54\pm10.79 & 64.25\pm3.94 & 77.06\pm4.21 \\\hline \end{array}$	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	


#### Zero-shot Abilities.


	MSD				KiTS23		In-house Dataset						
Method	Hepatic Vessel Tumor		Pancreas Cyst		Kidney Tumor		Liver Cyst		Kidney Stone		Gallbladder Tumor		
	DSC↑	NSD↑	DSC↑	NSD↑	DSC↑	NSD↑	DSC↑	NSD↑	DSC↑	NSD↑	DSC↑	NSD↑	
SAM† (Shaharabany & Wolf, 2024)	35.76	45.83	37.17	49.26	35.45	41.33	34.99	40.88	24.14	31.92	28.08	36.38	
SAM2† (Yamagishi et al., 2024)	35.93	45.88	38.42	50.85	35.67	41.88	35.29	41.25	25.50	33.74	28.57	36.62	
SaLIP* (Aleem et al., 2024)	39.65	48.71	41.92	53.06	38.64	44.91	37.71	44.26	27.24	36.61	30.84	38.97	
H-SAM* (Cheng et al., 2024)	45.58	54.24	46.87	57.91	44.21	50.39	43.75	50.20	29.23	38.11	32.17	40.05	
ZePT* (Jiang et al., 2024)	53.12	63.25	53.35	63.50	46.82	52.44	51.64	57.36	33.97	42.42	35.48	43.23	
Malenia	59.52	69.60	60.91	70.28	54.96	60.60	61.85	70.93	43.05	52.95	47.35	55.79	


## **Qualitative visualizations**




#### Results









#### **Results**







CT Image

**Ground Truth** 

Malenia

"Left Lung"

Incorrect Text of "Location"

Similarity Score: 0.01

"Right Lung"

Correct Text of "Location"

Similarity Score: 0.99





#### Conclusion

Malenia is a novel vision-language pre-training method designed for 3D zero-shot lesion segmentation.

Cross-domain and cross-modality challenges

Scalability to other imaging modalities

Handling lesions with ambiguous boundaries



Capturing complex visual semantics

**Generalization to diverse lesion types** 

Catching up the performance of fully supervised models.

www.shlab.org.cn



## Thanks!